Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015
Jamjoom Pharmaceuticals Factory — 9M 2025 Earnings Presentation
18 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, Oct 23, 2025
Slide 1: Earnings Presentation 9M 2025
Earnings Presentation 9M 2025 Jeddah | 23 October 2025
Slide 2: Business and Strategy Highlights
Business and Strategy Highlights
Slide 3: Disclaimer
3 Disclaimer This presentation has been prepared solely for use as an investor presentation for Jamjoom Pharmaceuticals Factory Company (the “Company”). By attending or by reading this presentation, you agree to be bound by the following limitations. The information contained in this presentation is
Slide 4: 9M 2025 Highlights: Consistent delivery of revenue and profitability
4 Business and Strategy Highlights 9M 2025 Highlights: Consistent delivery of revenue and profitability Revenue # of Brands +3 in Consumer Health Underpinned by successful execution of our +1 in Anti-Diabetic 9M 25 +13% YoY market penetration strategy across key 9M 25 +6 YTD +1 in Ophthalmology SAR
Slide 5: A look at our 2025 growth levers...
5 Business and Strategy Highlights A look at our 2025 growth levers... Portfolio Manufacturing Saudi Market Export Markets Enhancement • JP’s growth outpaces • Iraq and Gulf continue to • Strategic brands drive core • Jeddah main facility IQVIA KSA retail market1 make solid contributions business gr
Slide 6: Consistent revenue growth in core therapeutic areas and key markets
6 Business and Strategy Highlights Consistent revenue growth in core therapeutic areas and key markets Revenue Contribution by Country, YoY (SARmn) Revenue Contribution by Therapeutic Area, YoY (SARmn) +13% 95 22 14 8 1,196 1,059 +13% (3) 7 8 6 5 2 1,196 44 25 36 3 1,059 Rebounded Self-sufficiency 9
Slide 7: Expanding beyond niche: JP's portfolio diversification into high-value TAs
7 Business and Strategy Highlights Expanding beyond niche: JP’s portfolio diversification into high-value TAs 2021 Revenue Contribution by Therapeutic Area (SARmn) 9M 2025 Revenue Contribution by Therapeutic Area (SARmn) Pain & Inflammation C. Nervous System Anti-diabetic 26% 5% Ophthalmology 2% Oph
Slide 8: Monthly revenue growth for top KSA pharma since 2022 (44 months)
8 Business and Strategy Highlights Monthly revenue growth1 for top 5 KSA pharma since 2022 (44 months) Peer 1 19 negative months Peer 2 7 negative months 2 negative months Peer 3 17 negative months Peer 4 20 negative months Jan-22 Jul-22 Jan-23 Jul-23 Jan-24 Jul-24 Jan-25 Aug-25 Growth vs same month
Slide 9: Focused pipeline to propel JP into high value therapeutic areas
9 Business and Strategy Highlights Focused pipeline to propel JP into high value therapeutic areas Under SFDA review Ready for SFDA Submission Under Development Total 2 Ophthalmology 10 15 3 2 General Medicine 2 Revenue growth EBITDA margin Dermatology 2 4 2 Cardiometabolic TAs 2 Gastrointestinal 3
Slide 10: Positioning JP for long-term growth through strategic business development
10 Business and Strategy Highlights Positioning JP for long-term growth through strategic business development Selected key agreements signed No. Partner Product Type Therapeutic Area Coverage Model 1. Swiss-Based Biosimilar Cardiometabolic MENA License and supply with potential localization 2. UAE-
Slide 11: Financial Highlights
Financial Highlights
Slide 12: 3rd Quarter 2025 highlights: Delivering another quarter of healthy margins
12 Financial Highlights 3rd Quarter 2025 highlights: Delivering another quarter of healthy margins Revenue (SARmn) EBITDA (SARmn) +4% +11% 328 342 124 112 34.1% 36.3% EBITDA Margin 3Q 24 3Q 25 3Q 24 3Q 25 Gross Profit (SARmn) Net Profit (SARmn) +7% 209 +12% 194 107 Driven by 95 strategic brands offs
Slide 13: Operational efficiency to curtail employee costs upgrade…
13 Financial Highlights Operational efficiency to curtail employee costs upgrade… Total Cost Of Revenue Movement YoY (SARmn) Operating Expenses Movement YoY (SARmn) +12% +8% 7 444 12 10 350 12 4 324 3 24 397 Maintained S&D/Sales down G&A/Sales up R&D/Sales YoY 1.7 ppts YoY 0.3 ppts YoY +13% +5% +21%
Slide 14: … and continue upward momentum of margin expansion
14 Financial Highlights … and continue upward momentum of margin expansion EBITDA Movement YoY (SARmn) Quarterly Trend of Profitability (%) +22% EBITDA Margin 137 37.2% 64.0% 63.3% 61.0% 60.9% 12 445 59.3% EBITDA Margin 34.5% (47) (12) (10) 365 37.7% 37.5% 36.3% 34.1% 27.7% 34.3% 33.3% SAR 4.4m Impr
Slide 15: Scaling working capital to fuel high-growth trajectory
15 Financial Highlights Scaling working capital to fuel high-growth trajectory ▪ The cash conversion cycle (CCC) extended to 296 days, reflecting a 10.7% YoY increase (~15% Cash Conversion Cycle (Days) CAGR), driven by rising institutional sales and supplier alignment. driven by higher receivables a
Slide 16: Outlook and Guidance
Jamjoom Pharma LojLé pgaa Outlook and Guidance
Slide 17: Financial guidance: Strong momentum towards achieving upgraded targets
17 Outlook and Guidance Financial guidance: Strong momentum towards achieving upgraded targets FY 25 Guidance 9M 25 Actual Results Revenue growth 12-15% 13.0% 34-34.5% EBITDA margin 37.2% (previously 31.5-33%) CAPEX 4-6% 4.7% Dividend 50-60% payout ratio SAR 2 per share paid for 1H 25 (semi-annual)
Slide 18: Q&A
Q&A Tarek Hosni, Chief Executive Officer Anwer Mohiuddin, Chief Financial Officer Muhammad Bin Khalid, Assoc. Director – Finance & IR
Jamjoom Pharmaceuticals Factory — 9M 2025 Earnings Presentation on 6ix